DBV Technologies S.A. SEC filings DBVT
DBV Technologies S.A. has 576 filings in SEC EDGAR's recent list, going back to Jul 25, 2014. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | May 11, 2026 | Jun 3, 2026 |
| PRE 14A | Preliminary proxy statement | May 1, 2026 | Jun 3, 2026 |
| DEF 14A | Proxy statement | May 15, 2025 | Jun 11, 2025 |
| PRE 14A | Preliminary proxy statement | May 5, 2025 | Jun 11, 2025 |
| DEF 14A | Proxy statement | Apr 26, 2024 | May 16, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 8, 2024 | May 16, 2024 |
| DEF 14A | Proxy statement | Mar 24, 2023 | Apr 12, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 8, 2023 | Apr 12, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | May 12, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2022 | May 12, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEF 14A | Proxy statement | Apr 26, 2021 | May 19, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2021 | May 19, 2021 |
Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DBVT (Nasdaq), DBVTF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Chatillon
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1613780
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.